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Abstract: Transcription factors (TFs) bind DNA in a
sequence-specific manner and thereby regulate target
gene expression. TF binding and its regulatory activity is
highly context dependent, and is not only determined by
specific cell types or differentiation stages but also relies
on other regulatory mechanisms, such as DNA and chro-
matin modifications. Interactions between TFs and their
DNA binding sites are critical mediators of phenotypic
variation and play important roles in the onset of disease.
A continuously growing number of studies therefore at-
tempts to elucidate TF:DNA interactions to gain knowl-
edge about regulatory mechanisms and disease-causing
variants. Here we summarize how TF-binding characteris-
tics and the impact of variants can be investigated, how
bioinformatic tools can be used to analyze and predict
TF:DNA binding, and what additional information can be
obtained from the TF protein structure.
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Introduction
Transcription factors (TFs) are regulatory proteins that
bindDNA in a sequence-specificmanner. Alongwith chro-
matin accessibility and histone modification, TFs regulate
the expression of target genes depending on cell type, de-
velopmental stage, or external signals; for a detailed re-
view on the regulatory epigenome and histone modifica-
tions see [1, 2].
Over 1,000 potential TFs have been identified in hu-
mans. In general, TFs are highly conserved among species
and recognize specific nucleotide sequences or motifs in
non-coding regulatory regions of the genome. Binding is
based on the complementarity of the DNA sequence and
protein structure. As recognition sites are rather short,
usually 6–12 bases, and every TF has numerous bind-
ing sites throughout the genome, many TFs bind coop-
eratively as multimers to ensure highly specific and sta-
ble interactions. To add an additional layer of control to
the rigorously regulated process of gene expression, many
TFs recruit cofactors or depend on binding of specific lig-
ands [3].
Though the majority of the genomic DNA is usually
densely packed in nucleosomes and higher-order struc-
tures, making it inaccessible to TFs, a special class of TFs,
called “pioneer factors,” are able to bind to their recogni-
tion sites even in condensed chromatin. They thereby in-
duce changes to the chromatin structure that enable bind-
ing of other factors needed to initiate transcription [4]. To
amplify the expression of a protein-coding target gene,
TFs guide RNA polymerase II to gene promoter regions
to start the transcription process (Figure 1). TFs can also
block binding sites for other proteins and thereby, depend-
ing on the specific context, act as repressors. How DNA
sequence variants in TF binding sites impact site recog-
nition and transcriptional regulation is difficult to pre-
dict.
Though we tend to think of TFs as either occupying
particular sequences in the chromatin or not, many TFs
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Figure 1: Transcriptional activation is mediated by chromatin state and transcription factor binding. Densely condensed chromatin (closed)
prevents transcription factors and other proteins needed to initiate transcription from binding, thereby inhibiting gene expression. Open
chromatin on the other hand is accessible for proteins to bind to promoter and enhancer regions. Transcription factors can either directly
guide RNA polymerase II to promoter regions of target genes or work in cooperation with other factors and mediators to assemble a tran-
scription initiation complex. TF, transcription factor; Pol II, RNA polymerase II; CoF, cofactor; M, mediator.
are controlled in a more complex manner. Some TFs are
produced in response to external or internal stimuli in a
pulsed, oscillating, or sustained manner. Consequently,
the genes that are switched on by such TFs depend on
their expression dynamics [5, 6]. The TF MyoD, a mas-
ter regulatory factor of skeletal muscle known for its abil-
ity to initiate the muscle-specific differentiation program,
is one example. In proliferating muscle precursor cells,
MyoD oscillates with a periodicity of 2–3 hours, thereby
keeping the cells in an undifferentiated state. This oscil-
latory MyoD pattern changes before the cells differentiate.
When MyoD expression becomes sustained, cells start to
differentiate and undergo fusion into myotubes [7]. This
implies that the biological function of TF binding should
not only be investigated statically, but in a time resolved
fashion.
The impact of mutations in genes coding for TFs and
resulting structural changes of the proteins have been in-
vestigated and linked to diseases in many studies. Be-
cause the protein-coding exome covers less than 2% of
the human genome, the focus of variant analysis has been
expanded to non-coding regulatory regions (Krude et al.
this edition, Guo et al. this edition). Approximately 80%
of all genome-wide association study (GWAS) hits affect
the non-coding DNA and many of them are thought to act
through differential TF binding [8]. Although it is often
challenging to identify disease-associated variants and to
prove causation, several studies show that variants in the
regulatory genome alter TF:DNA interactions and are as-
sociated with altered target gene expression and disease
[9, 10]. This emphasizes the necessity of examining ge-
netic variants in the context of patient clinical phenotypes.
For example, single-nucleotide variants (SNVs) in the pro-
moter region of coagulation factor F9 have been associ-
ated with a specific subtype of the blood-clotting disor-
der hemophilia B. More than 20 different SNVs in three
distinct clusters affecting highly conserved base pair po-
sitions in the binding sites of the TFs HNF4α, ONECUT1/2,
and C/EBPα have been identified. All three binding sites
are in close proximity, and disruption of either one of
them significantly decreases promoter activity, indicating
a possible cooperation ofHNF4α, ONECUT1/2, andC/EBPα
to control F9 expression. This example shows how alter-
ations of single bases in TF-binding motifs can disrupt
TF:DNA interactions and critically alter gene expression
leading to disease [11].
Here, we review different in vitro and in vivo tech-
niques that can be used to investigate TF:DNA binding
characteristics and describe how the impact of variants on
the binding capacity can be measured. We outline the re-
cently made advances of bioinformatic tools and machine
learning approaches to predict and analyze TF-binding
sites (TFBSs) in the human genome. We further review
techniques for deriving quantitative TF:DNA affinity data
and discuss how they can be related to high-resolution
structures of TFs bound to their DNA targets. We finish by
discussing future challenges relating structures of target
DNA-bound TFs with quantitative affinity data.
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How can transcription factors and
their binding motifs be
investigated?
There are several techniques to identify potential reg-
ulatory domains with TFBSs and to assay chromatin
accessibility on a genomic scale. Widely used in an
ever-increasing number of publications are chromatin
immuno-precipitation followed by sequencing (ChIP-seq)
and the assay for transposase-accessible chromatin using
sequencing (ATAC-seq) (Guo et al. this edition).
ChIP-seq enables the study of protein:DNA interac-
tions and generates genome-wide maps of TFBSs or hi-
stone modifications. The technique depends on cross-
linking a protein of interest, e. g., a specific TF, to DNA
which is then fragmented. Using specific antibodies tar-
geting the protein of interest, protein-bound DNA frag-
ments are isolated and can be sequenced and mapped
back to the genome. ChIP-exo, a modification of the ChIP-
seq protocol, uses an exonuclease to trim the TF-bound
DNA, thereby improving the signal-to-noise ratio and the
resolution of TFBSs [12]. ChIP experiments can be uti-
lized for de novo motif discovery and provide informa-
tion about sites of high transcriptional activity and poten-
tial TF target genes in the cell of interest [13]. Data are al-
ready available for amultitude of TFs inmanydifferent cell
types, tissues, and conditions. Information about TF:DNA
interactions and discovered motifs are stored in numer-
ous open-access databases, such as JASPAR [14], and can
be employed for genome-wide studies (Garda et al. this
edition).
ATAC-seq was first established in 2013 and provides a
robust and uncomplicated alternative for methods such as
DNase I hypersensitive sites sequencing (DNase-seq) and
formaldehyde-assisted isolation of regulatory elements
coupledwith sequencing (FAIRE-seq), which require time-
consuming sample preparations and high amounts of in-
put material. ATAC-seq uses a hyperactive mutant of the
prokaryotic Tn5 transposase to cleave DNA in open chro-
matin regions and ligate it to sequencing adaptors. La-
beled DNA fragments are then purified, amplified, and se-
quenced, providing genome-wide profiles of chromatin ac-
cessibility [15] (Guo et al. this edition).
Recently, ATAC-seq has been used in single-cell ap-
proaches to further broaden the scope of experiments and
data resolution. In combination with single-cell RNA se-
quencing, this is a powerful tool to combine epigenomics
with transcriptomics and study cellular heterogeneity of
the regulatory landscape [16].
How can we measure transcription
factor:DNA interactions and the
impact of DNA variants on
transcription factor binding?
The ChIP-seq techniques map the TF-binding DNA sites
in a genome-wide fashion, but result in low spatial res-
olution and permit only limited assessment of binding
strength. They can also show some unspecific and/or
non-functional binding. That is why in vitro techniques
are employed to accurately measure TF:DNA interactions
and the impact of DNA variants on TF-binding. Ideally,
in vitro assays used for this purpose are able to accu-
rately determine the dissociation constants for both high-
and low-affinity binding [17]. A further issue is the scal-
ability of the assay. Screening large numbers of vari-
ants is still a challenge in terms of cost and time effi-
ciency.
Such tests require homogeneous and purified pro-
tein samples. As it is often difficult to express full-length
TFs at high levels [18], only the DNA-binding domain
(DBD) is usually expressed in a host system and further
purified using high-performance chromatography. To fa-
cilitate the purification, a peptide tag, most commonly
hexahistidine (His6) or glutathione S-transferase (GST),
is fused to either the N- or the C-terminus of the pro-
tein. In some cases, creating a fusion protein that includes
an additional solubility tag is necessary, and commonly
the purification and solubility tags are proteolytically re-
moved before the final purification stage, as they may in-
terfere with DNA binding or otherwise alter protein prop-
erties.
The electrophoretic mobility shift assay (EMSA) is
among the basic assays used for in vitro studies of pro-
tein binding to DNA. EMSA is a simple laboratory method
where the change in migration between free and protein-
bound DNA through a polyacrylamide or agarose gel is
assessed, as the speed of migration depends on the size,
charge, and, to a lesser extent, the shape of the analyzed
molecules or complexes. However, EMSAs are not suit-
able for analysis of large numbers of DNA variants and
do not easily yield dissociation constants. Fluorescence
anisotropy binding assays, on the other hand, enable the
determination of quantitative binding affinity data, but
they require the DNA variants to be fluorescently labeled,
which makes them suboptimal for analyzing a large num-
ber of DNA variants (Figure 2A).
Methods that have been successfully used to deter-
mine dissociation constants (KD values) for TF:DNA affin-
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Figure 2: Selection of methods used to experimentally assess TF:DNA interactions. (A) Simplified functional scheme and an example of typi-
cal results from methods for investigating specific DNA sequences: electrophoretic mobility shift assay (EMSA), microscale thermophoresis
(MST), and isothermal titration calorimetry (ITC). (B) Simplified schemes of high-throughput approaches such as protein-binding microar-
rays (PBMs), Cognate Site Identifier (CSI), and evolution of ligands by exponential enrichment coupled with sequencing (SELEX-seq).
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ity include isothermal titration calorimetry (ITC) and mi-
croscale thermophoresis (MST). Due to the sensitivity of
KDmeasurement ranging frompM tomM,MSTwas proven
to be effective in quantitating both high- and low-affinity
binding events. It usually requires fluorescently labeled
protein, which may be easily obtained as a fusion pro-
tein, e. g., GFP-TF. For the ITC experiment neither the TF
nor the DNA needs to carry a fluorescent label. Nonethe-
less, larger amounts of both TF and DNA variants are re-
quired to determine the affinity (Figure 2A). However ef-
fective, neither ITC nor MST can be considered as op-
timal for testing a large number of variants in a single
experiment as it only determines the affinity of one lig-
and.
To test tens of thousands of double-stranded DNA (ds-
DNA) molecules, protein-binding microarrays (PBMs) are
most often used. Their main limitations are a lack of com-
mercially available chips and the need for a rather strin-
gent washing step, which may result in loss of TFs bind-
ing with low affinity (Figure 2B). An interesting variation
of PBMs is Cognate Site Identifier (CSI), which is based on
preparing amicrofabricated array displaying every permu-
tation of a dsDNA sequence of up to ten positional vari-
ants, assessing the effect on binding of each possible vari-
ant in the same experiment. Formore detailed information
about other methods that measure binding events occur-
ring on a surface see references [19, 20]. Those methods
are proven to be effective for all ranges of TF:DNA binding
affinities, but it should be noted that they often require us-
age of complementary methods that determine affinity in
solution [17].
Another approach to high-throughput measurements
of TF:DNA interactions is based on the generation of
high-complexity libraries of random or genomic DNA
fragments. Systematic evolution of ligands by exponen-
tial enrichment (SELEX) is commonly used for develop-
ment of the library (Figure 2B). It starts with the synthe-
sis of a gigantic library of randomly generated oligonu-
cleotides flanked by constant 5′ and 3′ ends that serve
as primers. After addition of the TF of interest, the se-
quences that did not bind are removed by affinity chro-
matography or by capturing the target on paramagnetic
beads. The bound sequences are amplified by PCR and
can undergo another round of more stringent selection
or can be sequenced immediately, depending on the
method variant. To learn more about library-based high-
throughput TF:DNA interaction measurement methods
see reference [21].
How can bioinformatics approaches
predict transcription factor binding
sites and the impact of non-coding
variants on binding?
Bioinformatics approaches facilitate processing of large
datasets and data integration to exploit the potential of
a growing body of data sources in order to predict TFBSs
and the impact of human genomic variants. The input to
such bioinformatic tools includes high-throughput data
from methods that map DNA binding specificities of TFs.
The most widely used datasets for this purpose are de-
rived from ChIP-seq, ChIP-exo, or SELEX experiments. Po-
tentials for the integration of suchdatasetswith additional
databases are abundant (Garda et al. this issue). For in-
stance, they can be combined with data that more broadly
map open chromatin based on DNA footprints, such as
from ATAC-seq or DNase-seq. In addition, the informa-
tion can be overlaid with databases that cover disease-
associated variants with the goal of identifying potential
disease mechanisms (Garda et al. this edition).
To discover or map TFBSs and predict the impact of
non-coding variants on binding, a multitude of bioinfor-
matic methods is available. For example, enumeration-
based approaches (e. g., Yeast Motif Finder)mapword-like
definitions of motifs across chromatin sequences. They
may introduce degenerate positions andmotifs of variable
length, but they are computationally intense and lack flex-
ibility [22]. In contrast, probabilistic methods work with
positional weight matrices (PWMs), which assign proba-
bilities to each base of the DNA sequence at different po-
sitions. Analysis of large sets of TF-associated DNA se-
quences can be used to de novo predict PWMs associated
with this TF. This can be achieved by PWM-based tools,
such as MEME (Figure 3A) [23]. These approaches are lim-
ited in the setting of very large datasets and highly depend
on the TF under scrutiny [24].
Recent years havewitnessed dramatic advances in the
field of deep learning, which offers scalable and flexible
computational approaches for pattern discovery and op-
erates on large amounts of sequence data. Deep learn-
ing enables integration of high-throughput datasets of
TF-binding and open chromatin with databases of ge-
nomic variants to facilitate prediction of DNA–protein as-
sociations and to anticipate the impact of non-coding
variants on these interactions. For instance, DeepBind
uses convolutional neural networks to predict DNA–pro-
tein interactions [25]. In this approach, which is based
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Figure 3: Position weight matrices and mutation maps provide infor-
mation about transcription factor-binding motifs and the impact of
single-nucleotide variants. (A) Position weight matrix of a transcrip-
tion factor derived from de novomotif discovery provided by MEME.
(B) Example of a mutation map highlighting the predicted impact of
sequence variants in a heatmap (red indicates increased binding;
blue indicates decreased binding). Single-nucleotide variants are
highlighted in the map. SNV, single-nucleotide variant.
on tools originally developed for image classification, ge-
nomic sequences are treated as fixed-length sequencewin-
dows composed of four channels (A, C, G, T). DeepBind
uses a set of sequences of variable lengths and, for each
sequence, an experimentally determined binding score,
which can be quantitative measurements or binary class
labels. For training, DeepBind is supplied with large DNA
sequence datasets, often of terabyte size, which can be
derived from diverse approaches, including ChIP-seq and
SELEX. Following training, DeepBind can score new se-
quences, including human genome regions from refer-
ence genomes or from individuals with genetic diseases.
Recently, improved deep learning-based approaches have
been developed to provide single-nucleotide resolution
maps, e. g., a mutation map (Figure 3B). They consist of
an importance score for each nucleotide variant at each
position that is directly linked to prediction and therefore
provide an easy-to-interpret visualization of the predicted
variant effect on the binding affinity (for a recent review
see [26]).
Structural studies of binding site
recognition by transcription factors:
How do they relate to quantitative
affinity data and how can they
inform binding site prediction
algorithms?
High-resolution structures of target DNA-bound TFs yield
tremendous insight into the molecular basis of these
proteins’ ability to recognize their specific promoter or
enhancer sequences and to discriminate against non-
cognate sequences or close variants, e. g., SNVs, of the
target sequence. Determination of these structures relies
on sophisticated, well-established, but low-throughput
analytical techniques: X-ray diffraction yields the high-
est spatial resolution, but requires single crystals of the
TF:DNA complex; nuclear magnetic resonance (NMR)
spectroscopy provides structures with more limited spa-
tial resolution, but also yields insight into complexdynam-
ics; and single-particle cryo-electron microscopy (cryo-
EM) has recently joined the methods allowing to derive
atomic models of macromolecular complexes [27, 28]. Al-
though a large number of TF:DNA complex structures are
known and deposited in the Protein Data Bank (PDB),1
for all the structural detail they reveal these structures
are of limited use for assessing the impact of SNVs on
TF binding because they typically only display TF bind-
ing to high-affinity and consensus DNA sites, leaving non-
specific binding or SNVs unstudied.
Crystal, NMR, or cryo-EM structures of TF:DNA com-
plexes allow an intimate view into the protein:DNA inter-
face that determines binding specificity (Figure 4A). The
most obvious source of specificity is the pattern of hy-
drogen bonds formed by the protein backbone or side
chains with the polar base pair edges exposed in the
grooves of dsDNA. Hydrogen bonds and salt bridges to the
sugar-phosphate backbone of the DNA are generally non-
specific, but contribute to the overall TF affinity for its tar-
get site (Figure 4B). Van der Waals contacts between TF
and cognate DNA are less directed; collectively, they de-
1 https://www.rcsb.org/
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Figure 4: Crystal structure of GRHL1 (PDB ID: 5MPF) in complex with a DNA fragment. (A) Binding of the Grainyhead Like Transcription Factor
1 (GRHL1) dimer (shades of blue) to its DNA target site and the shape complementarity between TF and DNA (yellow). (B) Example of hydro-
gen bonds crucial for target sequence recognition.
fine the shape complementarity between TF and dsDNA
and thereby contribute to the overall binding energy.
Future challenges
A particular challenge rests in relating structures of tar-
get DNA-bound TFs with quantitative affinity data as de-
scribed above. It is usually possible to ascertain that the
structure of a TF:TFBS complex is biologically relevant
by mutating key residues of the protein or the DNA as
identified by structure analysis and assaying the subse-
quent binding behavior. Taking the example of the Grainy-
head/CP2 transcription factors, proteins of core interest
to us, both protein and DNA variants lacking crucial in-
teracting residues were clearly deficient in binding as de-
termined by EMSA, ITC, and in vivo reporter assays [29].
However, it is considerably more difficult to derive accu-
rate binding energies for a TF:DNA complex from crystal
structures. Themain reason for this lies in the fact that the
various contacts at the TF:DNA interface are closely related
to the thermodynamic binding enthalpy, but do not allow
to assess the entropic contributions to the free energy of
binding, which arise from restricting the conformational
space of TF and DNA in a complex and from solvation and
desolvation effects, and hence the dissociation constant of
a complex.
The ability to derive affinity parameters from TF:DNA
structures is crucial for supporting efforts towards pre-
dicting the consequences of SNVs for gene regulation
through a specific TF. If these predictions aim to go be-
yond the establishedmotif findingmethods based on large
databases and sequence similarity, as described above,
they will probably have to integrate structural and bio-
physical data along with large-scale sequencing results.
At present, we cannot be sure how these algorithms could
be designed. Artificial intelligence (AI) is currently revo-
lutionizing many fields of computational biology, includ-
ing the prediction of three-dimensional protein structures
from linear sequences, an achievement considered highly
improbable until very recently [30]. If ways can be found
to muster the immense computer power required to do
such calculations, AI may contribute to predict the conse-
quences of SNVs on TF binding, gene regulation, and, ulti-
mately, disease associations. This detailed understanding
of the impact of genomic variants on patient phenotypes
will increase themolecular diagnosis rate for patientswith
suspected rare genetic disease, leading to improved medi-
cal management for patients and their families.
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